Abstract
The clinical efficacy of tazobactam/piperacillin (TAZ/PIPC), a combination of piperacillin and a new, β-lactamase inhibitor, tazobactam, for injection, was investigated in 10 patients with bacterial respiratory tract infections. The diagnosis in these patients was bacterial pneumonia in 6, pulmonary suppuration in 1, DPB in 1 and mycoplasmal pneumonia in 2. Mycoplasmal pneumonia was excluded as non-adaptive.
TAZ/PIPC was given in a daily doses of 2.5-5g by drip for 30-60 minutes intravenously, for 5 to 15 days.
Clinical efficacy was rated as excellent in 4, good in 3 and fair in 1. Bacteriological effects were evaluated in five cases. Four causative organisms were eradicated after administration of TAZ/PIPC.
Adverse reactions were not observed in any case. Abnormal laboratory findings included eosinophilia in 2 cases and increased GPT in 1, however, all of the reactions were mild. From these studies, it can be concluded that TAZ/PIPC is an effective and useful antibiotic for bacterial respiratory tract infections.
